Atlas Trials

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Clinical trial NCT03316586 · COMPLETED

Trial details

NCT number
NCT03316586
Sponsor
Dana-Farber Cancer Institute
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2017-11-30
Primary completion
2019-08-30
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.